455 Mission Bay Blvd South
About Twist Bioscience
Twist Bioscience synthesizes genes from scratch, known as “writing” DNA. Just as children learn to both read and write, the next phase of development for the genomics revolution is the ability to write DNA.
At Twist Bioscience, we work in service of people who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals and data storage, our unique silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers.
Twist Bioscience synthesizes genes from scratch on silicon, known as “writing” DNA. Just as children learn to both read and write, the next phase of development for the genomics revolution is the ability to write DNA to advance discovery and development across multiple industries.
55 articles with Twist Bioscience
Twist Bioscience Reports First Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress
Reports Record Revenue of $11.5 Million for First Quarter of Fiscal 2019
Announces Executive Promotions of Mark Daniels, Patrick Finn, Ph.D., and Patrick Weiss
Twist Bioscience Chief Technology Officer Presented at Praesens Foundation Future Health Threats Initiative 2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Bill Peck, Ph.D., chief technology officer, participated in the Future Health Threats Initiative 2019, a conference designed to encourage public-private cooperation to strengthen health security in Africa.
Twist Bioscience Receives ISO 13485:2016 and 9001:2015 Certifications of its Quality Management Systems for NGS Target Enrichment Panels
-- Expands Potential Serviceable Market to Include Companies Requiring Certification
Twist Bioscience Enhances Genes Product Offering with Longer Genes and Offers Access to Its Application Programming Interface
In addition, Twist is making its Application Programming Interface available for all customers ordering genes.
Twist Bioscience (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th at 1:30 p.m. Pacific Time in San Francisco.
Twist Bioscience to Report Fiscal 2018 Fourth Quarter and Full Year Financial Results on Wednesday, December 19, 2018
The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time
Twist Bioscience (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Emily Leproust, Ph.D., chief executive officer, will participate in an analyst-led fireside chat at the Evercore ISI HealthCONx Conference on Thursday, November 29, 2018 at 8:45am Eastern Time at the Boston Harbor Hotel in Boston, MA.
Mr. Johannessen brings more than 25 years of executive and financial leadership experience in the semiconductor industry, including expertise in operational execution, financial controls, fundraising and international business.
Twist Bioscience Corporation today announced that it has priced its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share, before underwriting discounts and commissions.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
Twist Bioscience Adds Ray Tabibiazar, M.D., as Senior Vice President, Corporate Development and Business Strategy
“Ray has been working with us as an advisor for two years, and we are thrilled to have him join us full time as we expand our focus on biologics drug discovery,” said CEO Emily M. Leproust, Ph.D.
Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.
The week of June 18 to June 22 was bookended by a big hiring announcement in the pharma industry. It began with a former Cowen analyst being tapped as chief financial officer of startup Allogene and ended with the retirement announcement of the group worldwide chairman at Johnson & Johnson.
Appoints James Thorburn as Chief Financial Officer
“The synthetic biology and next-generation sequencing markets are growing rapidly in Asia Pacific, and we are now poised to serve customers in Japan, Korea, India and Hong Kong,” says CEO.
Twist Bioscience Completes $50 Million Financing to Fuel Advancement of Digital Storage in DNA and Drug Discovery
Completion of a private placement of $50 million, brings the total raised to $259 million since the company’s founding in 2013.
The office will support sales and marketing as well as other corporate administrative functions and will be the headquarters for customer support for the company’s recently-launched solutions to enhance next-generation sequencing.
Twist Bioscience Launches Exome and Custom Target Enrichment Solutions for Genomics and Clinical Researchers Conducting Next-Generation Sequencing
Twist Bioscience today announced the commercial availability of several new products to enhance next-generation sequencing including its Twist Human Core Exome Kit.